These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 32951662)
1. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings. Tan AP Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662 [TBL] [Abstract][Full Text] [Related]
2. The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia. Ma Y; Zhou H; Zhang J; Zhang Q; Li Y; Xie R; Zhang B; Shen Z; Li P; Liang A; Zhou K; Han L; Hu Y; Xu K; Sang W; Wang X Front Immunol; 2024; 15():1448709. PubMed ID: 39399502 [TBL] [Abstract][Full Text] [Related]
3. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347 [TBL] [Abstract][Full Text] [Related]
4. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia. Tan AP Pediatr Blood Cancer; 2020 Nov; 67(11):e28635. PubMed ID: 32770654 [TBL] [Abstract][Full Text] [Related]
5. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. Gu T; Hu K; Si X; Hu Y; Huang H WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757 [TBL] [Abstract][Full Text] [Related]
8. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease. Pehlivan KC; Duncan BB; Lee DW Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708 [TBL] [Abstract][Full Text] [Related]
9. Neuroimaging of complications arising after CD19 chimeric antigen receptor T-cell therapy: A review. Pinto SN; Liu CJ; Nelson MD; Bluml S; Livingston D; Tamrazi B J Neuroimaging; 2023; 33(5):703-715. PubMed ID: 37327044 [TBL] [Abstract][Full Text] [Related]
10. Severe persistent neurotoxicity associated with CAR T therapy in children. Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536 [TBL] [Abstract][Full Text] [Related]
11. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532 [TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]
13. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. Ruff MW; Siegler EL; Kenderian SS Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871 [TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021. Gauthier J; Turtle CJ Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068 [TBL] [Abstract][Full Text] [Related]
15. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Hay KA Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609 [TBL] [Abstract][Full Text] [Related]
16. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076 [TBL] [Abstract][Full Text] [Related]
17. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies. Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062 [TBL] [Abstract][Full Text] [Related]
18. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S; Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170 [TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. Rubinstein JD; Krupski C; Nelson AS; O'Brien MM; Davies SM; Phillips CL Biol Blood Marrow Transplant; 2020 Nov; 26(11):e280-e285. PubMed ID: 32755637 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]